Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Relapsing-remitting Multiple Sclerosis Patients Over 8 Years: Care-MS Ii Follow-up (topaz Study)

R. Alroughani, B. A Singer, S. Broadley, S. Eichau, H. Hartung, E. K. Havrdova, H. J. Kim, K. Nakamura, C. Navas, C. Pozzilli, A. Rovira